Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05673785 · OUTCOME

Number of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) · Source last updated 2026-06-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.

Analysis population: The immunogenicity analysis set consisted of participants who received at least 1 dose of any of the study treatments and had an ADA status assessment at baseline and at least 1 postbaseline sample.

Groups in this outcome

Brentuximab Vedotin + CHP

Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin + CHP52

Reported measurements

Baseline Positive and Post-baseline Negative
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin + CHP1Not reportedNot reportedNot reportedNot reported
Baseline Negative and Post-baseline Negative
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin + CHP51Not reportedNot reportedNot reportedNot reported
Baseline Positive and Post-baseline Transiently Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin + CHP0Not reportedNot reportedNot reportedNot reported
Baseline Negative and Post-baseline Transiently Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin + CHP0Not reportedNot reportedNot reportedNot reported
Baseline Positive and Post-baseline Persistently Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin + CHP0Not reportedNot reportedNot reportedNot reported
Baseline Negative and Post-baseline Persistently Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin + CHP0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Baseline Positive and Post-baseline Negative
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        51
    title
    Baseline Negative and Post-baseline Negative
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Baseline Positive and Post-baseline Transiently Positive
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Baseline Negative and Post-baseline Transiently Positive
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Baseline Positive and Post-baseline Persistently Positive
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Baseline Negative and Post-baseline Persistently Positive
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
groups
  1. description
    Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.
    id
    OG000
    title
    Brentuximab Vedotin + CHP
param Type
COUNT_OF_PARTICIPANTS
population Description
The immunogenicity analysis set consisted of participants who received at least 1 dose of any of the study treatments and had an ADA status assessment at baseline and at least 1 postbaseline sample.
reporting Status
POSTED
time Frame
Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.
title
Number of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice